ASCO 2023 | Addressing the lack of sarcoma biomarkers

Junqiang Yin, MD, PhD, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, explains that there is a lack of biomarkers for patients with sarcoma. Sarcomas lack biomarkers and have high heterogeneity, as most unique genes are specific for single patients. Therefore, it is challenging to assign a panel for sarcoma. Tumor-informed techniques allow for biomarker-driven patient treatment and care. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.